🧾 What This Document Is

This is an amended registration statement (S-1/A) for Sonoma Pharmaceuticals. Think of it as the final, updated blueprint for selling new stock to the public. Its main purpose is to detail a planned public offering of "units," where each unit is a bundle containing one share of common stock and one warrant (the right to buy another share later). The company aims to raise about $5 million from this sale.

Why it matters: This filing signals the company needs capital. It's a legal requirement to ensure potential investors get all critical information before buying in.

🏢 What The Company Does

👉 In simple terms, Sonoma Pharmaceuticals is a specialty biopharmaceutical company. They develop and market therapies for skin conditions, chronic wounds, and ENT (ear, nose, and throat) diseases. Their technology platform is based on stabilized hypochlorous acid (HOCl), a substance that helps manage inflammation and infection.

They are a small-cap, "smaller reporting company" traded on Nasdaq under the ticker SNOA. Based in Boulder, CO, they are led by CEO Amy Trombly.

💰 Financial Highlights of the Offering

The core financial event here is the capital raise:

• Units Offered: Up to 2,024,291 units.
• Assumed Price: $2.47 per unit (based on the stock's closing price on March 18, 2026).
• Gross Proceeds: Approximately $5 million.
• Net Proceeds: Estimated at $4.48 million after paying the underwriter's 7.5% commission ($375k) and other expenses ($150k).
• Key Metric - Dilution: New investors buying at $2.47 will face immediate dilution of $0.36 per share compared to the company's adjusted net tangible book value.

Why it matters: The company is raising cash, but at a cost: existing shareholders' ownership percentage will shrink, and new buyers are paying more than the current stated net asset value per share.

🚀 Key Moves in This Offering

This isn't a simple stock sale. The structure includes two special features:

1. Warrants (The "Sweetener"): Each unit includes a common warrant to buy one more share at an exercise price set at 100% of the unit price. These expire in five years. This gives investors a potential extra upside if the stock price rises.
2. Pre-Funded Warrants: For large buyers who don't want to exceed ownership thresholds (like 4.99%), they can buy a Pre-Funded Warrant instead of a share upfront. This acts like a placeholder, letting them effectively buy the share later for a tiny $0.0001 fee.

Why it matters: The warrants can lead to more dilution later if exercised. The pre-funded warrant is a tool to attract big institutional investors without triggering regulatory reporting rules.

📦 Financial Position & Use of Proceeds

The filing gives a snapshot of the company's finances as of December 31, 2025:

• Cash: $2.56 million (pro forma $2.73M after some recent sales).
• Total Liabilities: $10.19 million.
• Stockholders' Equity: $3.43 million. The "pro forma as adjusted" column shows that after this offering, cash is expected to jump to about $7.2 million, and equity to $8.07 million.

Use of Proceeds: The net $4.48 million will be used for "working capital and general corporate purposes." This is a catch-all that includes funding operations, R&D, and capital needs.

Why it matters: The company is in a net-loss position (accumulated deficit of $200.4M) and needs this cash to fund its ongoing business. This offering significantly boosts its cash runway.

🔮 What's Next & Key Dates

• Offering Completion: The securities will be delivered "on or before" a date to be determined in May 2026.
• Underwriter's Option: The underwriter, Dawson James Securities, Inc., has 45 days to buy up to 15% more units (an additional ~303,643 units) to cover extra demand.
• Lock-Up Period: The company and its executives have agreed not to sell more stock for 90 days after the offering closes, to prevent flooding the market.
• No Warrant Market: The warrants and pre-funded warrants will NOT be listed on any exchange, making them illiquid and hard to sell.

Why it matters: The lock-up period provides temporary stability for the stock price. The lack of a warrant market means those securities are essentially "buy and hold" until you decide to exercise them.

⚖️ Big Picture: Strengths & Risks

👍 Strengths / Positives:

• Cash Infusion: Provides critical funding to continue operations and pursue growth.
• Market Listing: Maintains its listing on the Nasdaq Capital Market, which is important for credibility and liquidity.
• Defined Strategy: The technology platform has applications in multiple therapeutic areas.

⚠️ Significant Risks:

• Heavy Dilution: This offering dilutes existing shareholders, and future exercises of warrants/options will dilute them further. The stock price may drop due to the increased supply of shares.
• Nasdaq Compliance Threat: The company notes Nasdaq is considering a new rule requiring a $5 million minimum market value. Sonoma's current market cap is near that line, and failure to maintain listing would severely hurt its ability to raise capital.
• Financial Losses & Going Concern: The company has a long history of losses ($200.4M accumulated deficit), and its auditors have highlighted doubt about its ability to continue as a "going concern" without sufficient financing.
• Speculative Warrants: The warrants are described as "speculative in nature." Their value is uncertain, and they come with complex terms and no public market.

🔍 The Details: Underwriter's Deal

The deal with Dawson James Securities has important terms:

• They receive a 7.5% commission on gross proceeds.
• They get a "Underwriter's Warrant" to buy 5% of the total securities sold at an exercise price 110% of the offering price. This is extra compensation.
• They are engaging in potential stabilizing transactions (buying shares in the market) to support the offering price.

Why it matters: The underwriter's interests are aligned to complete the offering successfully, but their warrants and potential market actions add complexity.

🧠 The Analogy

Imagine Sonoma is a small, specialized kitchen that's run out of ingredients and cash. To stay open, they're selling "Dinner Kits" to customers. Each kit (a unit) contains a meal voucher (a share) and a coupon for a future discounted meal (a warrant). They raise enough cash to buy more ingredients (working capital), but they've now promised more future meals to more people, which will dilute the value of each meal ticket if everyone redeems their coupons.

🧩 Final Takeaway

Sonoma Pharmaceuticals is raising ~$4.5 million in much-needed cash through a complex stock-and-warrant offering to fund its ongoing operations. While this bolsters its short-term finances, it comes at the significant cost of diluting existing shareholders and highlights the company's precarious position as a small, loss-making entity facing potential Nasdaq delisting risks. The offering is a lifeline, but not a cure for underlying financial challenges.